Two Years to Build or Pay 200% — Which US Pharma Stocks Win? - AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN)

Two Years to Build or Pay 200% — Which US Pharma Stocks Win? - AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN)

Trump mandates U.S. manufacturing for generics within 2 years or tariffs climb to 200% by 2029; India supplies 50%+ of U.S. generics. Generic makers' thin margins cannot absorb 200% levies, risking market exit and shortages; Amgen and AbbVie gain durable competitive edge.